Clinuvel Pharmaceuticals Ltd ADR (CUVL)
Clinuvel Pharmaceuticals Ltd ADR is a depositary receipt representing common stock of Clinuvel Pharmaceuticals Limited, a biopharmaceutical company listed on OTC Markets. The underlying company develops and commercializes treatments for patients with genetic, metabolic, systemic, and life-threatening disorders across Australia, Europe, the United States, Switzerland, and other international markets. Its lead product candidate is SCENESSE, a systemic photoprotective drug for preventing phototoxicity in adults with erythropoietic protoporphyria (EPP). The company also advances a pipeline that includes CUV9900, PR
Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ
Jump directly to the stock analysis sections supported by the latest available data.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Overall Financial Health | Dividend Yield | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-CUVL
|
$8.99
|
55.1% Upside
|
Bargain
|
Not available
|
Not available
|
Great
|
0.5%
|
12.3x
|
1.5x
|
4.4x
|
296.1 M
|
114.8 M
|
0.5%
|
87.0%
|
24.0
|
7.4%
|
104.1%
|
